Revolution Medicines, Inc.

Revolution Medicines, Inc. reported its quarterly results for the period ending September 30, 2026. The company generated $197.6 million in product revenue for the nine months ended September 30, 2026, marking its first significant revenue generation following the August 2026 launch of RASONQUE®. Despite the new revenue stream, the company reported a net loss of $1.51 billion for the same period, an increase from the previous year, driven by substantial investments in research and development and selling, general, and administrative expenses. The company's cash position improved, with cash and cash equivalents reaching $615.9 million.

Revolution Medicines announced the U.S. FDA approval and commercial launch of RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic cancer. The drug generated $197.6 million in net product revenue in its first partial quarter. Additionally, the company received a positive CHMP opinion recommending marketing authorization for daraxonrasib in the European Union. Revolution Medicines reported a net loss of $407.5 million for the third quarter of 2026, with cash reserves of $3.7 billion. The company also highlighted progress in its clinical pipeline, including FDA Breakthrough Therapy Designation for a combination therapy.

Revolution Medicines reported a significant increase in net loss for the second quarter of 2026, reaching $(644.4) million, up from $(247.8) million in the prior year. The diluted net loss per share was $(3.06). Despite the growing losses, the company substantially strengthened its liquidity position through a public offering that generated $1.65 billion in net proceeds and the issuance of convertible senior notes for $487.1 million. As a result, cash, cash equivalents, and marketable securities collectively surged to $3.94 billion by June 30, 2026.

Revolution Medicines, Inc. announced its financial results for Q2 2026, reporting a net loss of $644.4 million and a strong cash position of $3.9 billion. The company achieved significant clinical and regulatory milestones, including FDA acceptance of the New Drug Application for daraxonrasib in metastatic pancreatic cancer and Breakthrough Therapy Designation for daraxonrasib in previously treated RAS mutant NSCLC. Additionally, positive clinical data was reported for zoldonrasib and elironrasib in non-small cell lung cancer, supporting planned Phase 3 studies. The company also updated its full year 2026 GAAP operating expense guidance to $2.1 billion to $2.2 billion.

Revolution Medicines announced its Q2 2026 financial results and significant corporate progress. The U.S. FDA accepted the New Drug Application for daraxonrasib for metastatic pancreatic cancer and granted Breakthrough Therapy Designation for daraxonrasib in RAS mutant non-small cell lung cancer. The company also achieved U.S. commercial launch readiness and reported encouraging clinical data for elironrasib and zoldonrasib in NSCLC. While R&D and G&A expenses increased, leading to a higher net loss, the company maintains a strong cash position of $3.9 billion.

Revolution Medicines, Inc. announced it will report its financial results for the second quarter of 2026 on Wednesday, August 5, 2026, after market close. Following the release, the company's senior management will host a webcast and conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the live and archived webcast via the company's investor relations website.

Revolution Medicines announced that the European Medicines Agency (EMA) has initiated a phased review of its investigational drug, daraxonrasib, for pancreatic cancer, aiming to accelerate its assessment. This follows the drug's designation as an orphan medicinal product and high priority under EMA’s Cancer Medicines Pathfinder. Concurrently, the company is nearing completion of its rolling New Drug Application (NDA) submission to the U.S. FDA under the Commissioner’s National Priority Voucher pilot program. These regulatory advancements are supported by positive Phase 3 RASolute 302 trial results, which demonstrated improved overall and progression-free survival.

Revolution Medicines announced positive Phase 1/2 clinical trial results for zoldonrasib in combination regimens for RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC). The zoldonrasib plus chemotherapy regimen in previously untreated patients demonstrated compelling antitumor activity, with an 82% objective response rate (ORR) with mFFX and 61% with GnP. The zoldonrasib plus daraxonrasib combination in previously treated patients achieved a 50% ORR in the second-line cohort and 47% in the third-line-plus cohort, with promising progression-free survival. These findings support the ongoing RASolute 305 and planned RASolute 309 Phase 3 trials.

Revolution Medicines announced it will present new data from its RAS(ON) pipeline at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress. The presentations include two oral presentations from Phase 1/2 trials evaluating zoldonrasib in combination regimens for metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). Additionally, two Phase 3 trials-in-progress posters for daraxonrasib in PDAC will be featured, highlighting its potential as a monotherapy or in combination for first-line treatment and as an adjuvant therapy.

Revolution Medicines announced that Dr. Steve Kelsey, President of Research and Development, will retire effective January 4, 2027, transitioning to a new role as Senior Advisor to the CEO on July 1, 2026. The company also held its Annual Meeting, where stockholders elected two Class III directors, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approved executive compensation on a non-binding, advisory basis.